3 Biotech Stocks That Could Be Multibaggers in the Making: July Edition

But the risks certainly match the rewards. One of the main characteristics of biotech companies is that they depend heavily on drug approvals from the Food and Drug Administration (FDA) and patent protection upon treatment development, which makes it difficult to predict the future outlook of individual stocks. Biotech companies also need heavy investment into research and development (R&D) in order to remain competitive, which requires high cash reserves and aggressive borrowing. Moderna (MRNA) Using its M ...